The trial supports the feasibility of randomized trials for tocilizumab as a treatment for ICB-induced colitis and arthritis.317 Additionally, the use of JAK and STAT3 inhibitors combined with ICB in advanced cancers, exemplified by ruxolitinib-alleviated ICB-associated myocarditis, underscores the potential of targeting the IL-6/JAK/STAT3 signaling pathway to augment antitumor immunity and address the adverse inflammatory effects of ICB treatment.318,319 This evolving paradigm suggests a synergistic potential that could redefine treatment strategies for patients with advanced-stage cancers. This evidence concerns the gene STAT3 and arthritic joint disease.